Synapse Open Synapse
Biology

Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer

Nature Communications · · 1 min read

This study shows that tracking tumor DNA in blood can help predict outcomes, monitor treatment response, and reveal resistance in women receiving bireociclib plus fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer.

Latest from Nature Communications